homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

April 14, 2016

Adaptive Biotechnologies

Adaptive Biotechnologies named Charles Sang senior vice president, diagnostics. Sang will lead the diagnostics business strategy for the clonoSEQ Process. Tom Willis, PhD, will transition to an advisory role. Sang's experience is in hematology/oncology and rare diseases, and he was most recently vice president of global diagnostics for Nanostring Technologies.




Email or user name:
Password:
 
Forgot password? Click here.